NASDAQ:MRUS Merus (MRUS) Stock Price, News & Analysis $44.19 -1.26 (-2.77%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$46.32 +2.13 (+4.82%) As of 05/2/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Merus Stock (NASDAQ:MRUS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Merus alerts:Sign Up Key Stats Today's Range$44.19▼$46.3650-Day Range$34.89▼$49.1652-Week Range$33.19▼$61.61Volume705,630 shsAverage Volume712,091 shsMarket Capitalization$3.06 billionP/E RatioN/ADividend YieldN/APrice Target$85.31Consensus RatingBuy Company OverviewMerus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Read More… Merus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreMRUS MarketRank™: Merus scored higher than 68% of companies evaluated by MarketBeat, and ranked 609th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingMerus has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 14 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMerus has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Merus' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Merus are expected to decrease in the coming year, from ($3.85) to ($4.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merus is -11.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merus is -11.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerus has a P/B Ratio of 7.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Merus' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.60% of the float of Merus has been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Merus has recently decreased by 15.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMerus does not currently pay a dividend.Dividend GrowthMerus does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.60% of the float of Merus has been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Merus has recently decreased by 15.50%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News Sentiment0.85 News SentimentMerus has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 27 news articles for Merus this week, compared to 6 articles on an average week.Search Interest5 people have searched for MRUS on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows5 people have added Merus to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Merus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.57% of the stock of Merus is held by insiders.Percentage Held by Institutions96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Merus' insider trading history. Receive MRUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter. Email Address MRUS Stock News HeadlinesLeerink Partnrs Issues Negative Outlook for Merus EarningsMay 3 at 1:12 AM | americanbankingnews.comMerus N.V. Announces Interim Clinical Data for Petosemtamab with Pembrolizumab in PD-L1+ r/m HNSCC to be Presented at 2025 ASCO® Annual MeetingApril 23, 2025 | quiverquant.comElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.May 4, 2025 | Brownstone Research (Ad)Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual MeetingApril 23, 2025 | globenewswire.comMerus’s Strategic Positioning and Growth Potential Justifies Buy RatingApril 20, 2025 | tipranks.comIs Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now?April 17, 2025 | msn.comMerus: Riding The Bispecific Wave In OncologyApril 7, 2025 | seekingalpha.comMerus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | globenewswire.comSee More Headlines MRUS Stock Analysis - Frequently Asked Questions How have MRUS shares performed this year? Merus' stock was trading at $42.05 at the beginning of the year. Since then, MRUS shares have increased by 5.1% and is now trading at $44.19. View the best growth stocks for 2025 here. How were Merus' earnings last quarter? Merus (NASDAQ:MRUS) announced its earnings results on Thursday, February, 27th. The biotechnology company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.48. The biotechnology company had revenue of $9.14 million for the quarter, compared to analyst estimates of $10.57 million. Merus had a negative net margin of 680.61% and a negative trailing twelve-month return on equity of 38.89%. When did Merus IPO? Merus (MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers. Who are Merus' major shareholders? Merus' top institutional investors include TimesSquare Capital Management LLC (0.50%), Moody Aldrich Partners LLC (0.16%), Harbor Capital Advisors Inc. (0.09%) and Alps Advisors Inc. (0.07%). Insiders that own company stock include Sven Ante Lundberg, Harry Shuman and Peter B Silverman. View institutional ownership trends. How do I buy shares of Merus? Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Merus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Merus investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE), Jabil (JBL) and Disc Medicine (IRON). Company Calendar Last Earnings2/27/2025Today5/04/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRUS CIK1651311 Webwww.merus.nl Phone(130) 253-8800FaxN/AEmployees37Year FoundedN/APrice Target and Rating Average Stock Price Target$85.31 High Stock Price Target$109.00 Low Stock Price Target$67.00 Potential Upside/Downside+93.0%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($3.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-154,940,000.00 Net Margins-680.61% Pretax Margin-659.93% Return on Equity-38.89% Return on Assets-31.16% Debt Debt-to-Equity RatioN/A Current Ratio8.32 Quick Ratio8.32 Sales & Book Value Annual Sales$36.13 million Price / Sales84.61 Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book7.16Miscellaneous Outstanding Shares69,183,000Free Float65,335,000Market Cap$3.06 billion OptionableOptionable Beta0.94 Social Links Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:MRUS) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.